Spore.Bio
Spore.Bio (Spore Biotechnologies SAS) develops Louis, an AI-based microbiological detection device using proprietary TMSI spectral imaging technology. The Paris-based deeptech firm performs reagent-free microbial detection in under 10 minutes for food and beverage, cosmetics, and pharmaceutical manufacturers.
- Company typePrivate
- Founded2023
- HeadquartersParis, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spore.Bio does
Spore.Bio (legal entity Spore Biotechnologies SAS) is a Paris-based deeptech company founded in 2023 that has developed Louis, a tabletop microbiological detection device powered by its proprietary Transformer-Based Multimodal Spectral Imaging (TMSI) platform. The device detects, quantifies, and identifies living microorganisms in under 10 minutes by analyzing intrinsic fluorescence signals triggered via dual-wavelength illumination, eliminating the need for culture, enrichment, stains, or reagents. The company targets quality control and contamination management in food & beverage, cosmetics, and pharmaceutical manufacturing, with secondary positioning in water/environment monitoring and cell/gene therapy sterility testing.
The technology stack combines biophotonic hardware with a Transformer-based foundational AI model trained on millions of fields of view across diverse matrices and stress conditions, supported by NVIDIA compute infrastructure and research collaborations with Institut Pasteur and DeepMind. The commercial platform includes the Louis instrument, proprietary single-use consumables (high-precision capture modules), and a cloud dashboard providing 21 CFR Part 11 compliant data management with audit trails for regulated environments.
Spore.Bio operates a sales-led enterprise field sales motion with direct engagement, pilot programs, and multi-year contracts targeting QC Directors, Food Safety Managers, and C-suite buyers at large manufacturers. Revenue streams are hardware sales (Louis devices), recurring consumables, and a cloud data subscription. The company is headquartered in Paris with a US commercial team being built in New York, has raised approximately $35M (€29.9M) across a 2023 pre-seed led by LocalGlobe, a February 2025 Series A led by Singular, and a January 2026 Google.org AI for Science grant, and acquired spectral-data-science firm GreenTropism in February 2025. The team of 58 spans 18 nationalities with backgrounds in photonics, AI, and biology.
Spore.Bio firmographics
Firmographics- Name
- Spore.Bio
- Legal name
- Spore Biotechnologies SAS
- Website
- https://spore.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Spore.Bio (Spore Biotechnologies SAS) develops Louis, an AI-based microbiological detection device using proprietary TMSI spectral imaging technology. The Paris-based deeptech firm performs reagent-free microbial detection in under 10 minutes for food and beverage, cosmetics, and pharmaceutical manufacturers.
- Ownership category
- akta.pro rank
Spore.Bio industry classification
Industry- Product category
- Microbiology Testing Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826), Industrial Instruments For Measurement, Display, And Control (3823), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
- akta.pro secondary industries
- Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Microbiome & Metagenomics Services (HLAGANAH)
Keywords
Where Spore.Bio is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Spore.Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Revenue model
- Louis Device Sales: Sale of the Louis microbiological testing device - the world's first AI-based microbiological instrument for real-time pathogen detection in factories.
- Proprietary Consumables: Recurring revenue from single-use consumables (proprietary filters/capture modules) required for each test run on the Louis device.
- Cloud Dashboard & Data Services: Cloud-based microbial data dashboard providing real-time process improvement insights, trend tracking across sites, and 21 CFR Part 11 compliant data management.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Annual | Enterprise enterprise agreements |
| Other | Multi-year contract | Discovery call for pilot programs |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Spore.Bio product offering
Product offeringCore offering
Spore.Bio sells the Louis device, an AI-based microbiological detection instrument that detects, quantifies, and identifies living microorganisms in under 10 minutes without culture, enrichment, or dyes. The platform combines proprietary dual-wavelength illumination with a Transformer-based AI model to deliver reagent-free microbial testing for factory floors, supported by recurring single-use consumables and a 21 CFR Part 11 compliant cloud dashboard.
Product overview
Spore.Bio's product portfolio centers on Louis, the world's first AI-based microbiological detection device — a tabletop instrument built on the proprietary TMSI (Transformer-Based Multimodal Spectral Imaging) platform. Louis performs reagent-free, culture-free microbial detection, quantification, and identification in under 10 minutes by analyzing intrinsic fluorescence signals via a Transformer-based AI model. The platform targets quality control in food & beverage, cosmetics, pharmaceutical, and other manufacturing environments, replacing slow traditional culture methods with real-time monitoring. A cloud-connected dashboard enables data traceability, trend analysis, and cross-site oversight. The portfolio also includes Spore.Labs, an AI-native research division focused on public health applications including antimicrobial resistance (AMR) and microbiome research.
Differentiator
Problem solved
Functional benefit
Brands
- Spore.Labs: AI-native research division launched in January 2026 focused on public health challenges using photonics and AI for microbiology testing.
Products and services
- Louis The Louis device is the world's first AI-based microbiological detection instrument, a tabletop hardware device that detects, quantifies, and identifies living microorganisms in under 10 minutes. It uses label-free, reagent-free spectral imaging to replace slow culture-based methods with real-time quality control for factory floors in food & beverage, cosmetics, and pharmaceutical manufacturing.
- TMSI (Transformer-Based Multimodal Spectral Imaging) TMSI is the underlying technology platform powering Louis, combining dual-wavelength illumination that triggers intrinsic fluorescence with a Transformer-based AI model that analyzes multi-spectral signals and spatial context. It detects and identifies microorganisms without culture, enrichment, or dyes, delivering results in under 10 minutes for industrial quality control applications.
- Proprietary Consumables Single-use, ready-to-use proprietary filters/capture modules required for each test run on the Louis device. Designed to handle samples from purified water to complex beverages without clogging, and requiring no growth media or reagents.
- Cloud Dashboard and Data Services A cloud-based microbial data dashboard providing real-time process improvement insights, trend tracking across sites, and 21 CFR Part 11 compliant data management with secure access and audit trails. Delivered alongside the Louis device for continuous quality monitoring.
Quantifiable outcome
- Detection time reduced from 20 days to 10 minutes
- +4 more outcomes
Companies that use Spore.Bio
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles2 records
Spore.Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Spore.Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and minor.
- Institut PasteurmajorWorld-renowned microbiology research institution partnering with Spore.Bio for scientific collaboration and validation of detection technology.
- DeepMindmajorAI research powerhouse backing Spore.Bio's technology development in the application of machine learning to microbiology.
- NVIDIAmajorGPU and AI computing infrastructure partner providing hardware support for training AI models and computational requirements.
- STATION FminorWorld's largest startup campus in Paris providing infrastructure and ecosystem support.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Spore.Bio competitors and assessment
Company assessmentBroad incumbents
- bioMérieux: Global leader in industrial and clinical microbiology, with deep installed base of microbial detection instruments (e.g., TEMPO, VITEK) in food, pharma, and cosmetics QC labs. Direct overlap with Spore.Bio's industrial QC use cases across all three target verticals.
- Neogen Corporation: Food and animal safety testing company (merged with 3M Food Safety in 2022), offering rapid pathogen detection kits and instruments. Overlaps with Spore.Bio in food safety QC workflows.
- Becton Dickinson (BD): Major life sciences and diagnostics company with established industrial microbiology and sterility testing products serving pharma manufacturers — competes with Spore.Bio in pharmaceutical QC and batch release.
- Merck KGaA (MilliporeSigma): Provides a comprehensive portfolio of microbiology testing products, consumables, and rapid sterility solutions for pharmaceutical and food manufacturers — directly competes with Louis in pharma GMP labs.
- Thermo Fisher Scientific: Global life sciences instruments giant offering a wide range of microbiology, cell culture, and analytical instruments. Overlaps with Spore.Bio's analytical instrument positioning in pharma and food QC.
- Bio-Rad Laboratories: Established life science and clinical diagnostics company with a real-time PCR and digital PCR portfolio widely used for microbial detection in food, water, and pharma QC — competes with Louis's speed advantage.
Direct peers
- Hygiena: Specializes in rapid microbiology and ATP hygiene monitoring for food safety and beverage manufacturing — direct overlap with Spore.Bio's food & beverage and environmental monitoring use cases.
- R-Biopharm: Mid-cap German diagnostics company specializing in food and feed safety testing, including rapid microbiology and PCR-based pathogen detection — direct overlap in industrial food QC workflows.
Emerging players
- Clear Labs: AI-driven food safety testing company using next-generation sequencing for pathogen detection in food production. Closest emerging competitor applying AI/computational biology to industrial microbial testing.
Others
- Eurofins Scientific: World's largest food and pharmaceutical testing services network, operating centralized labs that perform conventional microbiology for manufacturers. Could be both a competitor (service-based testing) and a partner/distribution channel for Spore.Bio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Spore.Bio social profiles
Digital presenceSpore.Bio compliance and trust
Trust signalCompliance2 records
Spore.Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spore.Bio leadership team
Management profileNumber of profiles
Profiles5 records
Spore.Bio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spore.Bio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spore.Bio
What does Spore.Bio do?
Spore.Bio sells the Louis device, an AI-based microbiological detection instrument that detects, quantifies, and identifies living microorganisms in under 10 minutes without culture, enrichment, or dyes. The platform combines proprietary dual-wavelength illumination with a Transformer-based AI model to deliver reagent-free microbial testing for factory floors, supported by recurring single-use consumables and a 21 CFR Part 11 compliant cloud dashboard.
Is Spore.Bio a public or private company?
Spore.Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Spore.Bio founded?
Spore.Bio was founded in 2023. It employs 101 to 250 people.
Where is Spore.Bio based?
Spore.Bio is headquartered in Paris, France, in the Europe region.
How does Spore.Bio make money?
Three revenue lines are on record. Louis Device Sales are the primary driver. The others are proprietary Consumables and cloud Dashboard & Data Services.
Who are Spore.Bio's main competitors?
Broad incumbents on record are bioMérieux, Neogen Corporation, Becton Dickinson (BD), Merck KGaA (MilliporeSigma), Thermo Fisher Scientific and Bio-Rad Laboratories. Direct peers are Hygiena and R-Biopharm. Clear Labs is listed as an emerging player. Eurofins Scientific is listed as an others.
Does Spore.Bio have an API?
No public API is recorded for Spore.Bio.
What industry is Spore.Bio in?
Spore.Bio's product category is Microbiology Testing Instruments. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 334516 and its SIC code is 3826.